Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 10, 2010 - Issue 7
Submit an article Journal homepage
709
Views
104
CrossRef citations to date
0
Altmetric
Review

Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?

Annelies Van Rie Department of Epidemiology, University of North Carolina at Chapel Hill, NC 27599-7435, USA. [email protected]; Right to Care, Johannesburg, South Africa; Department of Epidemiology, University of North Carolina at Chapel Hill, NC 27599-7435, USA. [email protected]; Right to Care, Johannesburg, South Africa
,
Liesl Page-Shipp Right to Care, Johannesburg, South Africa
,
Lesley Scott University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa; University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa
,
Ian Sanne University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa; University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa
&
Wendy Stevens University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa; University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South Africa
Pages 937-946 | Published online: 09 Jan 2014

References

  • WHO. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2009. WHO, Geneva, Switzerland (2009).
  • WHO. Global Tuberculosis Control. A Short Update to the 2009 Report. WHO, Geneva, Switzerland (2009).
  • MathewP, Kuo YH, Vazirani B, Eng RH, Weinstein MP. Are three sputum acid-fast bacillus smears necessary for discontinuing tuberculosis isolation? J. Clin. Microbiol.40, 3482–3484 (2002).
  • Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.10, 663–669 (2006).
  • van Kampen SC, Anthony RM, Klatser PR. The realistic performance achievable with mycobacterial automated culture systems in high and low prevalence settings. BMC Infect. Dis.10, 93 (2010).
  • Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med.30, 701–716, viii (2009).
  • WHO. Strategic and Technical Advisory for Tuberculosis. Report of the Ninth Meeting. 9–11 November 2009. WHO, Geneva, Switzerland (2009).
  • Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int. J. Tuberc. Lung Dis.12, 1226–1234 (2008).
  • Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb. Mortal. Wkly Rep.58, 7–10 (2009).
  • Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE3, e1536 (2008).
  • Paramasivan CN, Lee E, Kao K et al. Experience establishing tuberculosis laboratory capacity in a developing country setting. Int. J. Tuberc. Lung Dis.14, 59–64 (2010).
  • Boehme CC, Nabeta P, Henostroza G et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J. Clin. Microbiol.45, 1936–1940 (2007).
  • Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin-resistance using on-demand, near patient technology. J. Clin. Microbiol.48(1), 229–237 (2010).
  • Blakemore R, Story E, Helb D et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol.48, 2495–2501 (2010).
  • Banada PP, Sivasubramani SK, Blakemore R et al. Containment of bioaerosol infection risk by the Xpert(R) MTB/RIF assay and its applicability to point-of-care settings. J. Clin. Microbiol. DOI: JCM.01053-10v1 (2010) (Epub ahead of print).
  • Xpert® MTB/RIF, package insert. Cepheid, CA, USA (2009).
  • Lebrun L, Mathieu D, Saulnier C, Nordmann P. Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis. Eur. Respir. J.10, 1874–1876 (1997).
  • Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med.363(11), 1005–1015 (2010).
  • Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med.177, 787–792 (2008).
  • WHO. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR‑TB). WHO, Geneva, Switzerland (2008).
  • Matthys F, Rigouts L, Sizaire V et al. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug-resistant tuberculosis. PLoS ONE4, e7954 (2009).
  • Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis – a molecular story. J. Med. Microbiol.47, 189–196 (1998).
  • Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int. J. Tuberc. Lung Dis.4, 481–484 (2000).
  • Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet369, 2042–2049 (2007).
  • Monkongdee P, McCarthy KD, Cain KP et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am. J. Respir. Crit. Care Med.180, 903–908 (2009).
  • Aabye MG, Ravn P, PrayGod G et al. The impact of HIV infection and CD4 cell count on the performance of an interferon g release assay in patients with pulmonary tuberculosis. PLoS ONE4, e4220 (2009).
  • Raby E, Moyo M, Devendra A et al. The effects of HIV on the sensitivity of a whole blood IFN-g release assay in Zambian adults with active tuberculosis. PLoS ONE3, e2489 (2008).
  • Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin. Infect. Dis.44, 94–102 (2007).
  • Ait-Khaled N, Alarcon E, Bissell K et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int. J. Tuberc. Lung Dis.13, 927–935 (2009).
  • Mtei L, Matee M, Herfort O et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin. Infect. Dis.40, 1500–1507 (2005).
  • Corbett EL, Bandason T, Cheung YB et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med.4, e22 (2007).
  • Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and ‘unmasking’ of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care Med.177, 680–685 (2008).
  • Lawn SD, Edwards DJ, Wood R. Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings. Clin. Infect. Dis.50, 124–125 (2010).
  • Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS23, 1875–1880 (2009).
  • Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS22, 1897–1908 (2008).
  • Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int. J. Tuberc. Lung Dis.14, 131–140 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.